Optiver Holding
ALXN

Optiver Holding’s Alexion Pharmaceuticals ALXN Stock Holding History

Optiver Holding’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-68
Closed -$12K – 836
2021
Q2 		$12K Sell
68
-16,821
-100% -$2.89M ﹤0.01% 432
2021
Q1 		$2.58M Buy
+16,889
New +$2.61M ﹤0.01% 130

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Optiver Holding's ALXN Position: Q3 2021 in Review

Optiver Holding sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 68 shares — an estimated $12K sold.

Optiver Holding first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $2.58M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Optiver Holding reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Optiver Holding sold 68 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12K.
  • Optiver Holding first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Optiver Holding's Alexion Pharmaceuticals position peaked at $2.58M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Optiver Holding's 13F filing for Q3 2021, filed 15 Nov 2021.